Nicholas Glover - 05 Jul 2022 Form 4 Insider Report for MEI Pharma, Inc. (MEIP)

Role
Director
Signature
/s/ Brian G. Drazba, as attorney in fact
Issuer symbol
MEIP
Transactions as of
05 Jul 2022
Net transactions value
$0
Form type
4
Filing time
07 Jul 2022, 16:27:09 UTC
Previous filing
06 Jul 2021
Next filing
12 Oct 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MEIP Stock Option (Right to Buy) Award $0 +87,500 $0.000000 87,500 05 Jul 2022 Common Stock 87,500 $0.5400 Direct F1
holding MEIP Stock Option (Right to Buy) 50,000 05 Jul 2022 Common Stock 50,000 $2.95 Direct F2
holding MEIP Stock Option (Right to Buy) 20,000 05 Jul 2022 Common Stock 20,000 $1.57 Direct F2
holding MEIP Stock Option (Right to Buy) 40,000 05 Jul 2022 Common Stock 40,000 $1.36 Direct F2
holding MEIP Stock Option (Right to Buy) 40,000 05 Jul 2022 Common Stock 40,000 $2.83 Direct F2
holding MEIP Stock Option (Right to Buy) 40,000 05 Jul 2022 Common Stock 40,000 $4.28 Direct F2
holding MEIP Stock Option (Right to Buy) 40,000 05 Jul 2022 Common Stock 40,000 $2.52 Direct F2
holding MEIP Stock Option (Right to Buy) 50,000 05 Jul 2022 Common Stock 50,000 $3.49 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options will vest in equal monthly installments over twelve months.
F2 All of such options are presently exercisable.